##### Table of Contents



UNITED STATES SECURITIES AND EXCHANGE COMMISSION
 WASHINGTON, DC 20549
 FORM 10-Q
 þ
    
    QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
 FOR THE QUARTERLY PERIOD ENDED JUNE 30, 2009
 or
 o
    
    TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
 FOR THE TRANSITION PERIOD FROM  TO
 Commission File Number: 001-33054
 TRUBION PHARMACEUTICALS, INC.
 (Exact name of registrant as specified in its charter)
 DELAWARE
    
    52-2385898(State or other jurisdiction of incorporation or organization)
    
    (IRS Employer Identification No.)2401 FOURTH AVENUE, SUITE 1050
SEATTLE, WASHINGTON
    
    98121(Address of registrants principal executive offices)
    
    (Zip Code)
 (206) 838-0500
(Telephone number, including area code)
 N/A
(Former Name, Former Address and Former Fiscal Year, if Changed Since Last Report)
 
 þ o
 o þ
  Large accelerated filer oAccelerated filer þNon-accelerated filer o(Do not check if a smaller reporting company)Smaller reporting company o o þ




---



##### 



TRUBION PHARMACEUTICALS, INC.
 INDEX
 PAGE NO.PART I. FINANCIAL INFORMATION
    
    
    3Item 1.
    
    Financial Statements
    
    
    3Balance Sheets as of June 30, 2009 and December 31, 2008
    
    
    3Statements of Operations for the Three and Six Months Ended June 30, 2009 and 2008
    
    
    4Statements of Cash Flows for the Six Months Ended June 30, 2009 and 2008
    
    
    5Notes to Financial Statements
    
    
    6Item 2.
    
    Managements Discussion and Analysis of Financial Condition and Results of
Operations
    
    
    10Item 3.
    
    Quantitative and Qualitative Disclosures About Market Risk
    
    
    18Item 4.
    
    Controls and Procedures
    
    
    19PART II. OTHER INFORMATION
    
    
    20Item 1A.
    
    Risk Factors
    
    
    20Item 4.
    
    Submission of Matters to a Vote of Security Holders
    
    
    34Item 6.
    
    Exhibits
    
    
    35SIGNATURES
    
    
    
    
    
    36EXHIBIT INDEXEX-31.1EX-31.2EX-32.1
  2




---



##### Table of Contents



PART I. FINANCIAL INFORMATION
 
 ITEM 1. FINANCIAL STATEMENTS
 TRUBION PHARMACEUTICALS, INC.
 
 BALANCE SHEETS
(In thousands, except share and par value)
 June 30, 2009
    
    
    December 31, 2008(unaudited)ASSETSCurrent assets:Cash and cash equivalents
    
    $
    31,888
    
    
    $
    29,969Investments
    
    
    5,586
    
    
    
    22,928Receivable from collaboration
    
    
    2,901
    
    
    
    3,084Prepaid expenses
    
    
    928
    
    
    
    2,112Total current assets
    
    
    41,303
    
    
    
    58,093Property and equipment, net
    
    
    7,608
    
    
    
    9,190Other assets
    
    
    6
    
    
    
    7Total assets
    
    $
    48,917
    
    
    $
    67,290LIABILITIES AND STOCKHOLDERS EQUITYCurrent liabilities:Accounts payable
    
    $
    2,264
    
    
    $
    301Accrued liabilities
    
    
    3,207
    
    
    
    4,981Accrued compensation
    
    
    1,458
    
    
    
    1,169Current portion of notes payable
    
    
    1,249
    
    
    
    1,302Current portion of deferred rent
    
    
    180
    
    
    
    180Current portion of deferred revenue
    
    
    4,873
    
    
    
    4,873Total current liabilities
    
    
    13,231
    
    
    
    12,806Non-current portion of notes payable
    
    
    7,627
    
    
    
    8,261Non-current portion of deferred rent
    
    
    45
    
    
    
    135Non-current portion of deferred revenue
    
    
    12,183
    
    
    
    14,620Commitments and contingencies
Stockholders equity :Preferred stock, $0.001 par value per
share; shares authorized  5,000,000;
issued and outstanding  none
    
    
    
    
    
    
    Common stock, $0.001 par value per share;
shares authorized  150,000,000; issued
and outstanding  18,110,418 at June 30,
2009 and 17,882,307 at December 31, 2008
    
    
    18
    
    
    
    18Additional paid-in capital
    
    
    125,990
    
    
    
    123,846Deferred stock-based compensation
    
    
    (9
    )
    
    
    (30
    )Accumulated other comprehensive income
    
    
    2
    
    
    
    103Accumulated deficit
    
    
    (110,170
    )
    
    
    (92,469
    )Total stockholders equity
    
    
    15,831
    
    
    
    31,468Total liabilities and stockholders equity
    
    $
    48,917
    
    
    $
    67,290
  3




---



##### Table of Contents



TRUBION PHARMACEUTICALS, INC.
 
 STATEMENTS OF OPERATIONS
(In thousands, except per share data)
(unaudited)
 Three Months Ended
    
    
    Six Months EndedJune 30,
    
    
    June 30,2009
    
    
    2008
    
    
    2009
    
    
    2008Revenue:Collaboration revenue
    
    $
    4,119
    
    
    $
    4,468
    
    
    $
    8,331
    
    
    $
    8,431Operating expenses:Research and development
    
    
    8,098
    
    
    
    8,390
    
    
    
    20,177
    
    
    
    15,905General and administrative
    
    
    2,621
    
    
    
    3,025
    
    
    
    5,731
    
    
    
    5,998Total operating expenses
    
    
    10,719
    
    
    
    11,415
    
    
    
    25,908
    
    
    
    21,903Loss from operations
    
    
    (6,600
    )
    
    
    (6,947
    )
    
    
    (17,577
    )
    
    
    (13,472
    )Interest income
    
    
    36
    
    
    
    480
    
    
    
    154
    
    
    
    1,215Interest expense
    
    
    (138
    )
    
    
    (165
    )
    
    
    (278
    )
    
    
    (343
    )Net loss
    
    $
    (6,702
    )
    
    $
    (6,632
    )
    
    $
    (17,701
    )
    
    $
    (12,600
    )Basic and diluted net loss per share
    
    $
    (0.37
    )
    
    $
    (0.37
    )
    
    $
    (0.99
    )
    
    $
    (0.71
    )Shares used in computation of
basic and diluted net loss per
share
    
    
    18,023
    
    
    
    17,851
    
    
    
    17,961
    
    
    
    17,841
  4




---



##### Table of Contents



TRUBION PHARMACEUTICALS, INC.
STATEMENTS OF CASH FLOWS
(In thousands)
(unaudited)
 Six Months EndedJune 30,2009
    
    
    2008Operating activities:Net loss
    
    $
    (17,701
    )
    
    $
    (12,600
    )Adjustments to reconcile net loss to net cash used in operating activities:Stock-based compensation expense
    
    
    2,089
    
    
    
    1,944Net amortization of premium/(discount) on investments
    
    
    6
    
    
    
    (94
    )Depreciation and amortization expense
    
    
    1,627
    
    
    
    1,656Changes in operating assets and liabilities:Receivable from collaboration
    
    
    183
    
    
    
    1,141Prepaid expenses and other assets
    
    
    1,185
    
    
    
    217Accounts payable
    
    
    1,963
    
    
    
    (410
    )Accrued liabilities and compensation
    
    
    (1,485
    )
    
    
    263Deferred revenue
    
    
    (2,437
    )
    
    
    (2,924
    )Deferred rent
    
    
    (90
    )
    
    
    (90
    )Net cash used in operating activities
    
    
    (14,660
    )
    
    
    (10,897
    )Investing activities:Purchases of property and equipment
    
    
    (38
    )
    
    
    (941
    )Purchases of investments
    
    
    (11,926
    )
    
    
    (47,372
    )Maturities of investments
    
    
    29,161
    
    
    
    31,309Net cash provided by (used in) investing activities
    
    
    17,197
    
    
    
    (17,004
    )Financing activities:Payments on notes payable
    
    
    (694
    )
    
    
    (1,269
    )Proceeds from exercise of stock options
    
    
    76
    
    
    
    81Net cash used in financing activities
    
    
    (618
    )
    
    
    (1,188
    )Net decrease in cash and cash equivalents
    
    
    1,919
    
    
    
    (29,089
    )Cash and cash equivalents at beginning of period
    
    
    29,969
    
    
    
    41,827Cash and cash equivalents at end of period
    
    $
    31,888
    
    
    $
    12,738Supplemental disclosure information:Cash paid for interest
    
    $
    272
    
    
    $
    342
  5




---



##### Table of Contents



TRUBION PHARMACEUTICALS, INC.
NOTES TO FINANCIAL STATEMENTS
(unaudited)
 1. Summary of Significant Accounting Policies
 Basis of Presentation
   Use of Estimates
  Recently Adopted Accounting Pronouncements
 Fair Value Measurements, or
 Accounting for Collaborative Arrangements Related to the Development and
Commercialization of Intellectual Property,
  
    
    FSP No. FAS 157-4, Determining Fair Value When the Volume and Level of
Activity for the Asset or Liability Have Significantly Decreased and
Identifying Transactions That Are Not Orderly, or FSP FAS 157-4,
provides additional guidance on measuring the fair value of financial
instruments when market activity has decreased and quoted prices may
reflect distressed transactions;
 6




---



##### Table of Contents




    
    FSP No. FAS 115-2 and FAS 124-2, Recognition and Presentation of
Other-Than-Temporary Impairments, or FSP FAS 115-2 and 124-2, amends
the other-than-temporary impairment guidance for debt securities.
Under FSP FAS 115-2 and 124-2, an other-than-temporary impairment is
now triggered when there is intent to sell the security, it is more
likely than not that the security will be required to be sold before
recovery in value, or the security is not expected to recover the
entire amortized cost basis of the security. If an entity does not
intend to sell the security, credit related losses on debt securities
that exist will be considered an other-than-temporary impairment
recognized in earnings, and any other losses due to a decline in fair
value relative to the amortized cost deemed not to be
other-than-temporary will be recorded in other comprehensive income;
and
    
    FSP No. FAS 107-1 and APB No. 28-1, Interim Disclosures about Fair
Value of Financial Instruments, or FSP FAS 107-1 and APB 28-1, expands
the fair value disclosures required for financial instruments to
interim reporting periods for publicly traded companies, including
disclosure of the significant assumptions used to estimate the fair
value of those financial instruments.
  Subsequent Events,
 2. Fair Value Measurements
  Level 1 
    
    Observable inputs for identical assets or liabilities such as quoted prices in active markets;Level 2 
    
    Inputs other than quoted prices in active markets that are either directly or indirectly observable; andLevel 3 
    
    Unobservable inputs in which little or no market data exists, therefore developed using estimates and
assumptions developed by us, which reflect those that a market participant would use.
  June 30, 2009
    
    Level 1
    
    
    Level 2
    
    
    Level 3
    
    
    TotalMoney market funds
    
    $
    32,001
    
    
    $
    
    
    
    $
    
    
    
    $
    32,001Government and agency debt securities
    
    
    
    
    
    
    3,086
    
    
    
    
    
    
    
    3,086Corporate debt securities
    
    
    
    
    
    
    2,500
    
    
    
    
    
    
    
    2,500Total
    
    $
    32,001
    
    
    $
    5,586
    
    
    $
    
    
    
    $
    37,587
 December 31, 2008
    
    Level 1
    
    
    Level 2
    
    
    Level 3
    
    
    TotalMoney market funds
    
    $
    27,444
    
    
    $
    
    
    
    $
    
    
    
    $
    27,444Government and agency debt securities
    
    
    
    
    
    
    12,424
    
    
    
    
    
    
    
    12,424Corporate debt securities
    
    
    
    
    
    
    13,003
    
    
    
    
    
    
    
    13,003Total
    
    $
    27,444
    
    
    $
    25,427
    
    
    $
    
    
    
    $
    52,871
 7




---



##### Table of Contents



Gross Unrealized
    
    
    Gross Unrealized
    
    
    Estimated FairJune 30, 2009
    
    Amortized Cost
    
    
    Gains
    
    
    Losses
    
    
    Market ValueCorporate debt securities
    
    $
    2,499
    
    
    $
    1
    
    
    $
    
    
    
    $
    2,500Government and agency debt securities
    
    
    3,085
    
    
    
    1
    
    
    
    
    
    
    
    3,086Money market funds
    
    
    32,001
    
    
    
    
    
    
    
    
    
    
    
    32,001Total
    
    
    37,585
    
    
    
    2
    
    
    
    
    
    
    
    37,587Less: cash equivalents
    
    
    (32,001
    )
    
    
    
    
    
    
    
    
    
    
    (32,001
    )Amounts classified as investments
    
    $
    5,584
    
    
    $
    2
    
    
    $
    
    
    
    $
    5,586
 Gross Unrealized
    
    
    Gross Unrealized
    
    
    Estimated FairDecember 31, 2008
    
    Amortized Cost
    
    
    Gains
    
    
    Losses
    
    
    Market ValueCorporate debt securities
    
    $
    12,940
    
    
    $
    63
    
    
    $
    
    
    
    $
    13,003Government and agency debt securities
    
    
    12,384
    
    
    
    40
    
    
    
    
    
    
    
    12,424Money market funds
    
    
    27,444
    
    
    
    
    
    
    
    
    
    
    
    27,444Total
    
    
    52,768
    
    
    
    103
    
    
    
    
    
    
    
    52,871Less: cash equivalents
    
    
    (29,935
    )
    
    
    (8
    )
    
    
    
    
    
    
    (29,943
    )Amounts classified as investments
    
    $
    22,833
    
    
    $
    95
    
    
    $
    
    
    
    $
    22,928
  3. Net Loss Per Share
  4. Collaboration Agreement
  8




---



##### Table of Contents



5. Restructuring
  9




---



##### Table of Contents



6. Comprehensive Income (Loss)
  Three months ended
    
    
    Six months endedJune 30,
    
    
    June 30,2009
    
    
    2008
    
    
    2009
    
    
    2008Net loss
    
    $
    (6,702
    )
    
    $
    (6,632
    )
    
    $
    (17,701
    )
    
    $
    (12,600
    )Net unrealized
losses on
securities
available-for-sale
    
    
    (22
    )
    
    
    (230
    )
    
    
    (101
    )
    
    
    (141
    )Net unrealized
gains (losses) on
cash flow hedges
    
    
    
    
    
    
    207
    
    
    
    
    
    
    
    (27
    )Comprehensive loss
    
    $
    (6,724
    )
    
    $
    (6,655
    )
    
    $
    (17,802
    )
    
    $
    (12,768
    )
 7. Subsequent Events
  
 ITEM 2. MANAGEMENTS DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
 This quarterly report on Form 10-Q contains forward-looking statements within the meaning of
Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange
Act of 1934, as amended, which are subject to the safe harbor created by those sections.
Forward-looking statements are based on our managements beliefs and assumptions and on information
currently available to them. In some cases you can identify forward-looking statements by terms
such as may, will, should, could, would, expect, plans, anticipates, believes,
estimates, projects, predicts, and potential, and similar expressions intended to identify
forward-looking statements. Examples of these statements include, but are not limited to,
statements regarding: the implications of interim or final results of our clinical trials, the
progress of our research programs, including clinical testing, the extent to which our issued and
pending patents may protect our products and technology, our ability to identify new product
candidates, the potential of such product candidates to lead to the development of commercial
products, our anticipated timing for initiation or completion of our clinical trials for any of our
product candidates, our future operating expenses, our future losses, our future expenditures for
research and development, and the sufficiency of our cash resources. Our actual results could
differ materially from those anticipated in these forward-looking statements for many reasons,
including the risks faced by us and described in Part II, Item 1A of this quarterly report on Form
10-Q and our other filings with the Securities and Exchange Commission, or SEC. You should not
place undue reliance on these forward-looking statements, which apply only as of the date of this
quarterly report on Form 10-Q . You should read this quarterly report on Form 10-Q completely and
with the understanding that our actual future results may be materially different from what we
expect. Except as required by law, we assume no obligation to update these forward-looking
statements, whether as a result of new information, future events, or otherwise.
 The following discussion and analysis should be read in conjunction with the unaudited
financial statements and notes thereto included in Part I, Item 1 of this quarterly report on Form
10-Q.
 Overview
 tm
 10




---



##### Table of Contents



tm
     11




---



##### Table of Contents



12




---



##### Table of Contents



Critical Accounting Policies and Significant Judgments and Estimates
   Revenue Recognition
  Up-Front Fees and License Fee.
 Collaborative Research Funding.
 Milestones.
 13




---



##### Table of Contents



Preclinical Study, Clinical Trial and Manufacturing Accruals
  
    
    fees paid to contract research organizations in connection with preclinical studies;
    
    fees paid to clinical research organizations and other clinical sites in connection
with clinical trials; and
    
    fees paid to contract manufacturers in connection with the production of components and
drug materials for preclinical studies and clinical trials.
  Stock-Based Compensation
 Share-Based
Payment
  Six months endedJune 30,2009
    
    2008Risk-free interest rate
    
    
    2.13%-2.64
    %
    
    
    2.80%-3.40
    %Weighted-average expected life (in years)
    
    
    5.98
    
    
    
    6.02Expected dividend yield
    
    
    0
    %
    
    
    0
    %Expected volatility rate
    
    
    88%-91
    %
    
    
    70%-73
    %Weighted-average estimated fair value of
employee options
    
    $
    1.04
    
    
    $
    5.58
  14




---



##### Table of Contents



Valuation of Investments
  Results of Operations for the Three Months and Six Months Ended June 30, 2009 and 2008
 Revenue
  Research and Development Expenses
   15




---



##### Table of Contents



Three months ended
    
    
    Six months endedJune 30,
    
    
    June 30,2009
    
    
    2008
    
    
    2009
    
    
    2008Research and preclinical programs
    
    $
    4,147
    
    
    $
    5,471
    
    
    $
    9,923
    
    
    $
    10,491Clinical development programs
    
    
    3,951
    
    
    
    2,919
    
    
    
    10,254
    
    
    
    5,414Total research and development
    
    $
    8,098
    
    
    $
    8,390
    
    
    $
    20,177
    
    
    $
    15,905
    General and Administrative Expenses
  16




---



##### Table of Contents



Net Interest Income (Expense)
  Liquidity and Capital Resources
  Operating Activities.
 Investing Activities.
 Financing Activities.
    17




---



##### Table of Contents




    
    the terms and timing of any additional collaborative or licensing agreements that we may
establish;
    
    the ability to raise capital through strategic partnerships or in the debt/equity
markets;
    
    milestone payments projected to be received under the Wyeth collaboration agreement;
    
    the scope, rate of progress, results and costs of our preclinical testing, clinical
trials, and other research and development activities;
    
    the number of programs we pursue;
    
    the cost of establishing clinical and commercial supplies of our product candidates;
    
    the cost of preparing, filing, prosecuting, defending, and enforcing any patent claims
and other intellectual property rights;
    
    the cost, timing, and outcomes of regulatory approvals; and
    
    the extent to which we acquire or invest in businesses, products, or technologies.
  
 ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK
   18




---



##### Table of Contents



ITEM 4. CONTROLS AND PROCEDURES
 Evaluation of disclosure controls and procedures.
 Changes in internal control over financial reporting.
 19




---



##### Table of Contents



PART II. OTHER INFORMATION
 
 Item 1A. Risk Factors
  Risks Related to Our Business
 If we fail to obtain the capital necessary to fund our operations, we may be unable to develop
our product candidates and we could be forced to share our rights to these product candidates
with third parties on terms that may not be favorable to us.
  We have incurred operating losses in each year since our inception and expect to continue to
incur substantial and increasing losses for the foreseeable future.
  Our success depends on the success of our clinical product candidates, TRU-015, TRU-016, and
SBI-087, and we cannot be certain that they will be safe or effective, complete clinical trials,
receive regulatory approval, or be successfully commercialized.
  20




---



##### Table of Contents



We depend on our collaborative relationship with Wyeth to develop, manufacture, and commercialize
TRU-015, SBI-087, and other selected product candidates.
    21




---



##### Table of Contents



The pending acquisition of Wyeth by Pfizer could have an adverse effect on our collaboration with
Wyeth or on our development of TRU-015, SBI-087 and other products in development under the Wyeth
collaboration agreement.
  Our success depends on the proper management of our current and future business operations, and
the expenses associated with them.
   We rely on highly skilled personnel, and if we are unable to retain or motivate key personnel or
hire qualified personnel, we may not be able to maintain our operations.
  22




---



##### Table of Contents



We currently rely on third-party manufacturers to supply our product candidates and will rely on
third-party manufacturers to manufacture our product candidates in commercial quantities, which
could delay or prevent the clinical development and future commercialization of our product
candidates.
    We cannot assure you any of our product candidates will be safe or effective, or receive
regulatory approval.
  23




---



##### Table of Contents



Any failure or delay in commencing or completing clinical trials for product candidates could
severely harm our business.
  
    
    having the capital resources available to fund additional clinical trials;
    
    our or our collaborators ability to obtain regulatory approval to commence a clinical
trial;
    
    our or our collaborators ability to manufacture or obtain from third parties materials
sufficient for use in preclinical studies and clinical trials;
    
    delays in patient enrollment and variability in the number and types of patients
available for clinical trials;
    
    poor effectiveness of product candidates during clinical trials;
    
    unforeseen safety issues or side effects;
    
    governmental or regulatory delays related to clinical trials, including trial design,
results, and materials supply;
    
    changes in regulatory requirements, policy, and guidelines; and
    
    varying interpretation of data by us, any or all of our collaborators, the FDA, and
similar foreign regulatory agencies.
  We rely on third parties to conduct our clinical trials. If these third parties do not perform as
contractually required or otherwise expected, we may not be able to obtain regulatory approval
for or commercialize our product candidates.
  24




---



##### Table of Contents



If we enter into additional strategic partnerships, such as our relationship with Wyeth, we may
be required to relinquish important rights to and control over the development of our product
candidates or otherwise be subject to terms unfavorable to us.
  
    
    we may not be able to control the amount and timing of resources that our strategic
partners devote to the development or commercialization of product candidates;
    
    strategic partners may delay clinical trials, design clinical trials in a manner with
which we do not agree, provide insufficient funding, terminate a clinical trial or abandon a
product candidate, repeat or conduct new clinical trials, or require a new version of a
product candidate for clinical testing;
    
    strategic partners may not pursue further development and commercialization of products
resulting from the strategic partnering arrangement or may elect to discontinue research and
development programs;
    
    strategic partners may not commit adequate resources to the marketing and distribution of
any future products, limiting our potential revenues from these products;
    
    disputes may arise between us and our strategic partners that result in the delay or
termination of the research, development, or commercialization of our product candidates or
that result in costly litigation or arbitration that diverts managements attention and
consumes resources;
    
    strategic partners may experience financial difficulties;
    
    strategic partners may not properly maintain or defend our intellectual property rights
or may use our proprietary information in a manner that could jeopardize or invalidate our
proprietary information or expose us to potential litigation;
    
    business combinations or significant changes in a strategic partners business strategy
may also adversely affect a strategic partners willingness or ability to complete its
obligations under any arrangement;
    
    strategic partners could independently move forward with a competing product candidate
developed either independently or in collaboration with others, including our competitors;
and
    
    strategic partners could terminate the arrangement or allow it to expire, which would
delay the development and may increase the cost of developing our product candidates.
  Our relationship with Wyeth may have a negative effect on our ability to enter into beneficial
relationships with third parties.
  If our technology or our product candidates conflict with the rights of others we may not be able
to manufacture or market our product candidates, which could have a material adverse effect on us
and on our collaboration agreement with Wyeth.
  25




---



##### Table of Contents



If we are unable to obtain, maintain, and enforce our proprietary rights, we may not be able to
compete effectively or operate profitably.
  
    
    obtain and maintain patent and other proprietary protection for our technology,
processes, and product candidates;
    
    enforce patents once issued and defend those patents if their enforceability is
challenged;
    
    preserve trade secrets; and
    
    operate without infringing the patents and proprietary rights of third parties.The degree of future protection for our proprietary rights is uncertain. For example:
    
    we might not have been the first to make the inventions claimed in our patents, if
issued, or disclosed in our pending patent applications;
 26




---



##### Table of Contents




    
    we might not have been the first to file patent applications for these inventions;
    
    others may independently develop similar or alternative technologies or duplicate any of
our technologies;
    
    it is possible that none of our pending patent applications will result in issued patents
or, if issued, these patents may not be sufficient to protect our technology or provide us
with a basis for commercially viable products, and may not provide us with any competitive
advantages;
    
    if our pending applications issue as patents, they may be challenged by third parties as
not infringed, invalid, or unenforceable under U.S. or foreign laws;
    
    if issued, the patents under which we hold rights may not be valid or enforceable; or
    
    we may develop additional proprietary technologies that are not patentable and that may
not be adequately protected through trade secrets, if, for example, a competitor were to
independently develop duplicative, similar, or alternative technologies.
     27




---



##### Table of Contents



We may incur substantial costs as a result of litigation or other proceedings relating to patent
and other intellectual property rights.
  We face substantial competition, which may result in others discovering, developing, or
commercializing products before, or more successfully than, we do.
  Product Candidates for Autoimmune and Inflammatory Diseases. ® ® ® ® ® ®
 Product Candidates for B-cell Malignancies. ® ® ® ®
  
    
    design and develop products that are superior to other products in the market;
    
    attract and retain qualified scientific, medical, product development, commercial, and
sales and marketing personnel;
    
    obtain patent and/or other proprietary protection for our processes, product candidates,
and technologies;
    
    operate without infringing the patents and proprietary rights of third parties;
    
    obtain required regulatory approvals; and
    
    successfully collaborate with others in the design, development, and commercialization of
new products.
 28




---



##### Table of Contents



We may fail to select or capitalize on the most scientifically, clinically, or commercially
promising or profitable product candidates.
  Even if our product candidates receive regulatory approval, they could be subject to restrictions
or withdrawal from the market and we may be subject to penalties if we fail to comply with
regulatory requirements or if we experience unanticipated problems with our products.
  
    
    restrictions on the products or manufacturing processes;
    
    withdrawal of the products from the market;
    
    voluntary or mandatory recalls;
    
    fines;
    
    suspension of regulatory approvals;
    
    product seizures; or
    
    injunctions or the imposition of civil or criminal penalties.
  Failure to obtain regulatory approval in foreign jurisdictions would prevent us from marketing
our products internationally.
  29




---



##### Table of Contents



Our product candidates may never achieve market acceptance even if we obtain regulatory
approvals.
  
    
    our ability to provide acceptable evidence of safety and efficacy;
    
    the prevalence and severity of adverse side effects;
    
    availability, relative cost, and relative efficacy of alternative and competing
treatments;
    
    the effectiveness of our marketing and distribution strategy;
    
    publicity concerning our products or competing products and treatments; and
    
    our ability to obtain sufficient third-party insurance coverage or reimbursement.
  If we are unable to establish a sales and marketing infrastructure or enter into collaborations
with partners to perform these functions, we will not be able to commercialize our product
candidates.
  
    
    our inability to recruit and retain adequate numbers of effective sales and marketing
personnel;
    
    the inability of sales personnel to obtain access to or persuade adequate numbers of
physicians to prescribe our products;
    
    the lack of complementary products to be offered by sales personnel, which may put us at
a competitive disadvantage relative to companies with more extensive product lines; and
    
    unforeseen costs and expenses associated with creating a sales and marketing
organization.
  30




---



##### Table of Contents



If any products we develop become subject to unfavorable pricing regulations, third-party
reimbursement practices, or healthcare reform initiatives, our business could be harmed.
  We face potential product liability exposure, and if successful claims are brought against us, we
may incur substantial liability for a product candidate and may have to limit its
commercialization.
  
    
    decreased demand for our product candidates;
    
    impairment of our business reputation;
    
    withdrawal of clinical trial participants;
    
    costs of related litigation;
    
    substantial monetary awards to patients or other claimants;
    
    loss of revenues; and
    
    the inability to commercialize our product candidates.
  We could be required to pay significant cancellation fees for reserved manufacturing capacity
under our manufacturing agreement with Lonza.
  31




---



##### Table of Contents



If we use biological and hazardous materials in a manner that causes contamination or injury or
violates laws, we may be liable for damages.
  Risks Related to Our Common Stock
 The trading price of our common stock may be subject to significant fluctuations and volatility,
and our stockholders may be unable to resell their shares at a profit.
  
    
    low trading volumes;
    
    our ability to develop and market new and enhanced product candidates on a timely basis;
    
    announcements by us or our collaborators or competitors of new commercial products,
clinical progress or the lack thereof, changes in or terminations of relationships,
significant contracts, commercial relationships, or capital commitments;
    
    commencement of, or our involvement in, litigation;
    
    changes in earnings estimates or recommendations by securities analysts;
    
    changes in governmental regulations or in the status of our regulatory approvals;
    
    any major change in our board or management;
    
    quarterly variations in our operating results or those of our collaborators or
competitors;
    
    general economic conditions and slow or negative growth of our markets; and
    
    political instability, natural disasters, war, and/or events of terrorism.
  32




---



##### Table of Contents



If securities analysts do not publish research or reports about our business, or if they
downgrade our stock, the price of our stock could decline.
  The concentration of our capital stock ownership with insiders will likely limit your ability to
influence corporate matters.
  Anti-takeover provisions in our charter documents and under Delaware law could make an
acquisition of us, which may be beneficial to our stockholders, more difficult and may prevent
attempts by our stockholders to replace or remove our current management.
  We are exposed to potential risks from legislation requiring companies to evaluate controls under
Section 404 of the Sarbanes-Oxley Act.
  33




---



##### Table of Contents



Item 4. Submission of Matters to a Vote of Security Holders
    FOR
    
    WITHHELDLee R. Brettman, M.D., FACP
    
    
    17,245,040
    
    
    
    32,876Anders D. Hove, M.D.
    
    
    17,245,040
    
    
    
    32,876Peter A. Thompson, M.D., FACP
    
    
    17,240,024
    
    
    
    32,892
  FOR
    
    17,262,340AGAINST
    
    10,560ABSTAIN
    
    5,016
 34




---



##### Table of Contents



ITEM 6. EXHIBITS
 ExhibitNumber
    
    Description3.1
    
    Amended and Restated Certificate of Incorporation (Exhibit 3.1)(A)3.2
    
    Amended and Restated Bylaws (Exhibit 3.1)(B)4.1
    
    Form of common stock certificate (Exhibit 4.1)(C)4.2
    
    Amended and Restated Investor Rights Agreement, dated July 13, 2004 (Exhibit 4.2)(A)4.3
    
    Amendment No. 1 to Amended and Restated Investor Rights Agreement, dated December 19, 2005 (Exhibit 4.3)(A)31.1*
    
    Certification of Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 200231.2*
    
    Certification of Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 200232.1*
    
    Certification of Chief Executive Officer and Chief Financial Officer pursuant to 18 U.S.C § 1350 as
adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
 
 (A)
    
    Incorporated by reference to the designated exhibit to the registrants Registration
Statement on Form S-1 filed with the SEC on June 2, 2006 (File No. 333-134709).(B)
    
    Incorporated by reference to the designated exhibit to the registrants Current Report on
Form 8-K filed with the SEC on November 26, 2008 (File No. 001-33054).(C)
    
    Incorporated by reference to the designated exhibit to the registrants Registration
Statement on Form S-1 filed with the SEC on October 2, 2006 (File No. 333-134709).*
    
    Filed herewith. 35




---



##### Table of Contents



SIGNATURES
  Date: August 6, 2009TRUBION PHARMACEUTICALS, INC.By:
    /s/ Michelle G. BurrisMichelle G. BurrisSenior Vice President and
Chief Financial Officer(Principal Accounting and Financial Officer) 36